首页> 外文期刊>Biological & pharmaceutical bulletin >Adverse Drug Events Caused by Drugs Contraindicated for Coadministration Reported in the Japanese Adverse Drug Event Report Database and Recognized by Reporters
【24h】

Adverse Drug Events Caused by Drugs Contraindicated for Coadministration Reported in the Japanese Adverse Drug Event Report Database and Recognized by Reporters

机译:在日本不利药物事件报告数据库中报告的毒品禁忌药物引起的不良药物事件,并由记者承认

获取原文
获取原文并翻译 | 示例
           

摘要

The "INTERACTIONS" section of package inserts aims to provide alert-type warnings in clinical practice; however, these also include many drug-drug interactions that occur rarely. Moreover, considering that drug-drug interaction alert systems were created based on package inserts, repeated alerts can lead to alert fatigue. Although investigations have been conducted to determine prescriptions that induce drug-drug interactions, no studies have focused explicitly on the adverse events induced by drug-drug interactions. We, therefore, sought to investigate the true occurrence of adverse events caused by drug pair contraindications for coadministration in routine clinical practice. Toward this, we created a list of drug combinations that were designated as "contraindications for coadministration" and extracted the cases of adverse drug events from the Japanese Adverse Drug Event Report database that occurred due to combined drug usage. We then calculated the reporter' recognition rate of the drug-drug interactions. Out of the 2121 investigated drug pairs, drug-drug interactions were reported in 43 pairs, 23 of which included an injected drug and many included catecholamines. Warfarin potassium and miconazole (19 reports), azathioprine and febuxostat (11 reports), and warfarin potassium and iguratimod (six reports) were among the 20 most-commonly reported oral medication pairs that were contraindicated for coadministration, for which recognition rates of drug-drug interactions were high. Although these results indicate that only a few drug pair contraindications for coadministration were associated with adverse drug events (43 pairs out of 2121 pairs), it remains necessary to translate these findings into clinical practice.
机译:包装插入的“交互”部分旨在在临床实践中提供警报型警告;然而,这些还包括很少发生的许多药物 - 药物相互作用。此外,考虑到药物 - 药物互动警报系统是基于包装插入而创建的,重复的警报可以导致警报疲劳。虽然已经进行了调查以确定诱导诱导药物 - 药物相互作用的处方,但没有关于药物 - 药物相互作用诱导的不良事件的研究。因此,我们试图调查常规临床实践中的药物对禁忌症引起的不良事件的真实发生。对此,我们创建了一份药物组合列表,被指定为“合作禁忌的禁忌症”,并从毒品使用组合发生的日本不利药物事件报告数据库中提取了不良药物事件的病例。然后我们计算了记者的药物 - 药物相互作用的识别率。在2121个中,将研究药物对,在43对中报道了药物 - 药物相互作用,其中23分包括注射药物,许多包括儿茶酚胺。 Warfarin钾和咪康唑(19份报告),AzathioPrine和Febuxostat(11个报告)和Warfarin Potassium和Iguratimod(六次报告)是20次常见的口服药物对成对的20对共同共同犯罪的对成对之一,其中占药物的识别率药物相互作用高。虽然这些结果表明,只有少数药物对共进的禁忌症与不良药物事件有关(2121对中的43对),但它仍然需要将这些发现转化为临床实践。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号